辉瑞正在研发新胆固醇药物托彻普，并希望其代替立普妥成为新一代拳头产品来拯救公司。 这是一场豪赌。
Pfizer had bet heavily that Torcetrapib, a novel cholesterol remedy it was developing, would be the blockbuster to replace Lipitor and help save the company.
就像大型生物技术公司健赞的首席执行官亨利·特米尔(Henri Termeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
因为百时美施贵宝仍将拥有ImClone公司的抗癌拳头产品Erbitux(爱必妥)北美市场的销售收益，这将使收购方无法获得该公司现有的大部分收益。
Because BMS will keep the North American marketing rights for Erbitux, ImClone's blockbuster cancer drug, much of the firm's current revenue will not go to the buyer.
应用推荐